Financials

  • Market Capitalization 1.16 B
  • Employee 88
  • Founded 2026
  • CEO Scott Davis
  • Website www.chronoscale.com
  • Headquarter California, United States
  • FIGI BBG002Z0NKK4
  • Industry N/A
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-47.14
Price to sales ratio
32.87

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2272
AVLN
Avalyn Pharma Inc. Common Stock
28.40 USD-1.05%-6.21%+13.06%+9.23%1.26 B USD
2316
DMC
Del Monte Corporation
24.9350 USD-0.99%-8.95%-11.55%-13.51%1.18 B USD
2353
AADX
Applied Aerospace & Defense, Inc.
6.40 USD-0.62%-19.29%-39.34%-69.16%1.10 B USD
2357
HOS
Hornbeck Offshore Services, Inc.
4.9350 USD-7.50%-16.57%-25.90%-55.66%1.10 B USD

Frequently asked questions about ChronoScale Holdings Corporation Common Stock

What is the ChronoScale Holdings Corporation Common Stock stock price today?

The current price of ChronoScale Holdings Corporation Common Stock (CHRN) is 7.95. Over the past 24 hours, the stock has changed by -6.58%. Follow the CHRN chart for real-time price dynamics.

What is the stock ticker of ChronoScale Holdings Corporation Common Stock?

ChronoScale Holdings Corporation Common Stock trades under the ticker CHRN. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is ChronoScale Holdings Corporation Common Stock stock going up?

CHRN has changed by -21.60% over the last week, -50.28% over the last month, and -46.28% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of ChronoScale Holdings Corporation Common Stock?

ChronoScale Holdings Corporation Common Stock currently has a market capitalization of 1.16 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were ChronoScale Holdings Corporation Common Stock earnings last quarter?

Last quarter, ChronoScale Holdings Corporation Common Stock reported earnings of -0.29 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was ChronoScale Holdings Corporation Common Stock revenue for the last quarter?

ChronoScale Holdings Corporation Common Stock reported quarterly revenue of 41.48 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was ChronoScale Holdings Corporation Common Stock net income for the last quarter?

ChronoScale Holdings Corporation Common Stock reported net income of -42.48 M for the last quarter. The previous quarter showed -103.45 M, which means net income changed by +58.93%.

How many employees does ChronoScale Holdings Corporation Common Stock have?

As of the latest available data, ChronoScale Holdings Corporation Common Stock has 88 employees. Workforce size can provide additional context about the company's scale and operations.

What is ChronoScale Holdings Corporation Common Stock EBITDA?

ChronoScale Holdings Corporation Common Stock EBITDA is -9.55 M, and its EBITDA margin is -23.02%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy ChronoScale Holdings Corporation Common Stock stock?

You can buy ChronoScale Holdings Corporation Common Stock (CHRN) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in ChronoScale Holdings Corporation Common Stock stock?

Investing in ChronoScale Holdings Corporation Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CHRN chart and related analysis on metatrader.com as part of your research.

ChronoScale Holdings Corporation Common Stock

Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk. Ekso Bionics currently focuses in the health and industrial sectors. The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community.